Tissue Plasminogen Activator for Thrombolytic Therapy: Expectation versus Reality

Krause J . Catabolism of tissue-type plasminogen activator (t-PA), its variants, mutants and hybrids. A review. Fibrinolysis 1988;2:133–42.

Bachmann F Kruithof EKO . Tissue plasminogen activator: Chemical and physiological aspects. Sem Thromb Haemost 1984;10:6–17.

Collen D Lijnen HR . Tissue-type plasminogen activator. Haemostasis 1986;16(Suppl 3):25–32.

Camiolo SM Thorsen S Astrup T . Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin and plasmin. Proc Soc Exp Biol Med 1971;38:277–80.

Collen D Stassen JM Verstraete M . Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis; effect of molecular form and dose of activator, age of the thrombus and route of administration. J Clin Invest 1983;71:368–76.

Urano T de Serrano VS Gaffney PJ Castellino FJ . Effectors of the activation of human (glu') plasminogen by human tissue plasminogen activator. Biochemistry 1988;27:6522–8.

Gaffney PJ Urano T de Serrano VS Mahmoud-Alexandroni M Metzger AR Castellino FJ . A role for chloride ion and fibrinogen in the activation of (glu') plasminogen in human plasma. Proc Natl Acad Sci USA 1988;85:3595–8.

Gaffney PJ Creighton LJ Mahmoud-Alexandroni M . Assays associated with fibrinolysis. In: Gaffney PJ Castellino FJ Plow E Takada A , eds. Fibrinolysis: Current prospects. London: Libby and Son, 1988:129–40.

Gascoine PS Harris R Gaffney PJ . Biological activities of recombinant and melanoma tissue plasminogen activator: An in vitro comparative study. Fibrinolysis 1988;2(Suppl 1):144 (Abst).

Marder VJ Sherry S . Thrombolytic therapy: Current status. N Engl J Med 1988;318:1585–95.

Gruppo Italiano per lo studio della streptochinasi nell' infarto miocardico (GISSI). Long term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI study. Lancet 1987;ii:871–4.

TIMI Study Group: The thrombolysis in myocardial infarction (TIMI) trial: Phase I findings. N Engl J Med 1985;312:932–6.

National Heart Foundation of Australia Coronary Thrombolysis Group. Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. Lancet 1988;i:203–7.

Van de Werf F Arnold AER . Intravenous tissue plasminogen activator and size of infarct, left ventricular function and survival in acute myocardial infarction. BMJ 1988;297:1374–9.

ISIS-2 (Second International Study of Infarct Survival). Collaborative group randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;ii:349–60.

AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction. Preliminary report of a placebo-controlled clinical trial. Lancet 1988;i:545–9.

Collen D Lijnen HR . Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991;78:3114–24.

The International Study Group (GISSI-2). Hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990;336:71–5.

ISIS-3. Reported at a press conference preceding the American College of Cardiology meeting in Atlanta, March 2 1991 (ISIS-3 press release).

Lijnen HR Collen D . Tissue-type plasminogen activator: Mutants, variants and adjunctive treatment. A review. Biotech Therapeut 1990;1:273–304.

Burdick MD Erickson LA Schaub RG . In vitro clot lysis activity of domain-deleted t-PA analogs produced by a partially synthetic cassette gene. Fibrinolysis 1988;2(Suppl 1):53 (Abst).

Nelles L Lijnen HR Collen D Holmes WE . Characterisation of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urinary-type plasminogen activator. J Biol Chem 1987;262:10855–62.

Lijnen HR Nelles L Van Hoef B Demarsin E Collen D . Characterisation of a chimaeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator (t-PA) and amino acids 138–411 of the single chain urokinase-type plasminogen activator (SCuPA). J Biol Chem 1988;263:19083–91.